STAT Plus: J&J to buy Momenta Pharma in a bid to bolster autoimmune disease pipeline
Health care giant Johnson & Johnson said Wednesday that it is acquiring Momenta Pharmaceuticals, gaining access to a promising experimental treatment for autoimmune diseases.
Momenta is being acquired for $52.50 per share, or a 73% premium to Tuesday’s closing price. The all-cash deal values the company at $6.5 billion.
